Tag: ASX: IMM
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Immutep gets green light for large-scale cancer product manufacturing for clinical trials
Immutep Limited, a clinical-stage biotechnology company specialising in LAG-3 immunotherapies for cancer and autoimmune diseases, has received regulatory authorisation for the commercial manufacturing of Eftilagimod Alpha (efti) at a scale of 2,000 litres for clinical trial use.
Featured Article
Automotive canopy and tray manufacturer manages 6,000 SKUs with self-implemented ERP
Australian automotive accessories manufacturer Trig Point self-implemented an ERP system in just three months and gained control over its unwieldy component inventory, product customizations, and production processes. “We wouldn’t be able to manage that without a system like this,” says Chris Wasylkiw, Production Engineer.
